Connor, Clark & Lunn Investment Management (CC&L)
ROIV icon

Connor, Clark & Lunn Investment Management (CC&L)’s Roivant Sciences ROIV Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-372,556
Closed -$3.93M – 1648
2024
Q1 		$3.93M Sell
372,556
-526,410
-59% -$5.68M 0.02% 488
2023
Q4 		$10.1M Buy
898,966
+120,001
+15% +$1.17M 0.05% 272
2023
Q3 		$9.1M Buy
778,965
+643,343
+474% +$7.27M 0.05% 268
2023
Q2 		$1.37M Buy
+135,622
New +$1.21M 0.01% 706

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ROIV Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Roivant Sciences (ROIV) in Q2 2024, closing a stake of 372,556 shares — an estimated $3.93M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ROIV in Q2 2023 and held it in 4 quarters. The position peaked at $10.1M in Q4 2023. 294 funds tracked by Wall St. Rank hold ROIV as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Roivant Sciences position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 372,556 Roivant Sciences shares in Q2 2024, an estimated $3.93M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Roivant Sciences in Q2 2023 and held it in 4 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Roivant Sciences position peaked at $10.1M in Q4 2023.
  • 294 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.